Outcomes of myeloablative allogeneic hematopoietic cell transplantation with omidubicel vs alternative donor sources

Outcomes of myeloablative allogeneic hematopoietic cell transplantation with omidubicel vs alternative donor sources

Abstract: Omidubicel is a nicotinamide-expanded stem cell product derived from umbilical cord blood (UCB). In a phase 3 randomized trial for high-risk hematologic malignancies, omidubicel had faster neutrophil engraftment and fewer infectious complications than standard UCB transplantation. However,...

Full description

Saved in:
Bibliographic Details
Main Authors: Chenyu Lin, Smitha Sivaraman, Gautam Sajeev, Yan Song, Chunyi Xu, Chujun He, James E. Signorovitch, Heayoung Shin, Xiao-Ying Tang, Mei-Jie Zhang, Linda J. Burns, Ronit Simantov, Mitchell E. Horwitz
Format: Article
Language:English
Published: Elsevier 2025-08-01
Series:Blood Neoplasia
Online Access:http://www.sciencedirect.com/science/article/pii/S2950328025000391
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items